BAX - Baxter Short-Term Debt to Capital

Baxter International is a medtech behemoth with a traditional culture that strictly adheres to FDA standards. The history of the short-term debt-to-equity ratio on the GURU.Markets chart allows for an assessment of financial stability, while 0.13 reflects the most recent value of the metric. Stable cash flow is driven by mature infusion systems segments, and revenue is based on global procurement by hospitals and dialysis centers.

The fundamental stability of Baxter International (BAX) is determined by the balance between operational efficiency and debt load. The trend of short-term loans relative to equity reflects the share of current liabilities within the capital structure, signaling the business's liquidity. An increase in this ratio may indicate refinancing risks. For Baxter International (BAX), this is critical during the modernization of plants to meet environmental standards and the transition to renewable energy.